DDInter32 DDInter1376
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Afatinib {u} (Compound) resembles {v} (Compound) Gefitinib
Afatinib {u} (Compound) binds {v} (Gene) ABCB1
Afatinib {u} (Compound) upregulates {v} (Gene) MTHFD2
Afatinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Afatinib {u} (Compound) downregulates {v} (Gene) IGFBP2
Afatinib {u} (Compound) causes {v} (Side Effect) Diarrhoea
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fosphenytoin
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Afatinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Afatinib {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) ERBB2
Afatinib (Compound) resembles Gefitinib (Compound)
Afatinib (Compound) binds ABCB1 (Gene)
Afatinib (Compound) upregulates MTHFD2 (Gene)
Afatinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Afatinib (Compound) downregulates IGFBP2 (Gene)
Afatinib (Compound) causes Diarrhoea (Side Effect)
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Afatinib may lead to a major life threatening interaction when taken with Lomitapide
Afatinib (Compound) binds ERBB2 (Gene) and Afatinib (Compound) downregulates ERBB2 (Gene)